Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose ketamine plus dexmedetomidine for pain control in limb trauma in the emergency department
IRCT20220120053770N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine and dexmedetomidine in Extremity Injuries and Acute traumatic pain, sponsored by Tehran University of Medical Sciences. Primary endpoint: Pain control effectiveness. Started Apr 2022; status: completed.
02
Drugs
ketaminedexmedetomidine
03
Conditions
Extremity InjuriesAcute traumatic pain
Beyond the preview
Go deeper on IRCT20220120053770N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220120053770N1.